Berwick DM: Disseminating Innovations in Health Care. JAMA. 2003, 289 (15): 1969-1975. 10.1001/jama.289.15.1969.
Article
PubMed
Google Scholar
Fuchs VR, Milstein A: The $640 Billion Question - Why Does Cost-Effective Care Diffuse So Slowly?. N Engl J Med. 2011, 364 (21): 1985-1987. 10.1056/NEJMp1104675.
Article
CAS
PubMed
Google Scholar
Kotchen TA: Why the Slow Diffusion of Treatment Guidelines Into Clinical Practice?. Arch Intern Med. 2007, 167 (22): 2394-2395. 10.1001/archinte.167.22.2394.
Article
PubMed
Google Scholar
Coleman J, Katz E, Menzel H: The Diffusion of an Innovation Among Physicians. Sociometry. 1957, 20 (4): 253-270. 10.2307/2785979.
Article
Google Scholar
Coleman J, Katz E, Menzel H: Medical Innovation: A Diffusion Study. 1966, The Bobbs-Merrill Company, Indianapolis
Google Scholar
Menzel H: Innovation, Integration, and Marginality: A Survey of Physicians. Am Sociol Rev. 1960, 25 (5): 704-713. 10.2307/2090143.
Article
Google Scholar
Winick C: The Diffusion of an Innovation Among Physicians in a Large City. Sociometry. 1961, 24 (4): 384-396. 10.2307/2785920.
Article
Google Scholar
Bastian H, Glasziou P, Chalmers I: Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?. PLoS Med. 2010, 7 (9): e1000326-10.1371/journal.pmed.1000326.
Article
PubMed
PubMed Central
Google Scholar
Fraser AG, Dunstan FD: On the impossibility of being expert. BMJ. 2010, 341.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010, 9: 203-214.
CAS
PubMed
Google Scholar
Brody H, Light DW: The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. Am J Public Health. 2011, 101 (3): 399-404. 10.2105/AJPH.2010.199844.
Article
PubMed
PubMed Central
Google Scholar
DeAngelis CD, Fontanarosa PB: Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence. JAMA. 2008, 299 (15): 1833-1835. 10.1001/jama.299.15.1833.
Article
CAS
PubMed
Google Scholar
Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA: Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest. 2010, 40 (2): 172-182. 10.1111/j.1365-2362.2009.02240.x.
Article
CAS
PubMed
Google Scholar
Lenzer J: Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011, 342: d2929-10.1136/bmj.d2929.
Article
PubMed
Google Scholar
Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue - Cohort Study. PLoS Med. 2010, 7 (10): e1000354-10.1371/journal.pmed.1000354.
Article
PubMed
PubMed Central
Google Scholar
Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI: Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med. 2010, 7 (10): e1000352-10.1371/journal.pmed.1000352.
Article
PubMed
PubMed Central
Google Scholar
Doumit G, Gattellari M, Grimshaw J, O'Brien MA: Local opinion leaders: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2007, 1: CD000125.
PubMed
Google Scholar
Mintzes B: For and against: Direct to consumer advertising is medicalising normal human experience. BMJ. 2002, 324 (7342): 908-909. 10.1136/bmj.324.7342.908.
Article
PubMed
PubMed Central
Google Scholar
Mintzes B, Barer ML, Kravitz RL, Kazanjian AE, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002, 324 (7332): 278-279. 10.1136/bmj.324.7332.278.
Article
PubMed
PubMed Central
Google Scholar
Prosser H, Almond S, Walley T: Influences on GPs' decision to prescribe new drugs–the importance of who says what. Fam Pract. 2003, 20 (1): 61-68. 10.1093/fampra/20.1.61.
Article
PubMed
Google Scholar
Prosser H, Walley T: New drug prescribing by hospital doctors: The nature and meaning of knowledge. Soc Sci Med. 2006, 62 (7): 1565-1578. 10.1016/j.socscimed.2005.08.035.
Article
PubMed
Google Scholar
Peay MY, Peay ER: Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Soc Sci Med. 1984, 18 (12): 1019-1025. 10.1016/0277-9536(84)90160-6.
Article
CAS
PubMed
Google Scholar
Peay MY, Peay ER: Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med. 1990, 31 (4): 467-476. 10.1016/0277-9536(90)90042-Q.
Article
CAS
PubMed
Google Scholar
Ratna N, Dray A, Perez P, Grafton R, Newth D, Kompas T: Diffusion and Social Networks: Revisiting Medical Innovation with Agents. Complex Decision Making. 2008, 30: 247-265.
Google Scholar
Dunn AG, Gallego B, Diffusion of competing innovations: The effects of network structure on the provision of healthcare. The Journal of Artificial Societies and Social Simulation. 2010, 13: 4.
Article
Google Scholar
Balas EA, Boren SA: Managing clinical knowledge for health care improvement. In: Yearbook of Medical Informatics 2000. Patient-Centered Systems. Edited by: Bemmel J, McCray AT. 2000, Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany, 65
Google Scholar
Birkett DJ, McManus P: Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. Br J Clin Pharmacol. 1995, 40 (4): 407-410. 10.1111/j.1365-2125.1995.tb04565.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, et al: Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA. 2006, 295 (4): 429-433. 10.1001/jama.295.4.429.
Article
CAS
PubMed
Google Scholar
Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E: Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?. N Engl J Med. 1992, 327 (4): 241-247. 10.1056/NEJM199207233270405.
Article
CAS
PubMed
Google Scholar
Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J: Impact of Clinical Trial Results on National Trends in β-Blocker Prescribing, 1996-2002. JAMA. 2004, 291 (1): 54-62. 10.1001/jama.291.1.54.
Article
CAS
PubMed
Google Scholar
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM: Use of Fibrates in the United States and Canada. JAMA. 2011, 305 (12): 1217-1224. 10.1001/jama.2011.353.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rogers EM: Diffusion of Innovations. 2003, Free Press, New York, 5
Google Scholar
Mahajan V, Muller E: Innovation Diffusion and New Product Growth Models in Marketing. J Mark. 1979, 43 (4): 55-68. 10.2307/1250271.
Article
Google Scholar
Mahajan V, Muller E, Bass FM: New Product Diffusion Models in Marketing: A Review and Directions for Research. J Mark. 1990, 54 (1): 1-26. 10.2307/1252170.
Article
Google Scholar
Meade N, Islam T: Modelling and forecasting the diffusion of innovation - A 25-year review. Int J Forecast. 2006, 22 (3): 519-545. 10.1016/j.ijforecast.2006.01.005.
Article
Google Scholar
Bass FM: A New Product Growth for Model Consumer Durables. Manag Sci. 1969, 15 (5): 215-227. 10.1287/mnsc.15.5.215.
Article
Google Scholar
Bass FM: Comments on "A New Product Growth for Model Consumer Durables": The Bass Model. Manag Sci. 2004, 50 (12): 1833-1840. 10.1287/mnsc.1040.0300.
Article
Google Scholar
Bemmaor AC, Lee J: The Impact of Heterogeneity and Ill-Conditioning on Diffusion Model Parameter Estimates. Mark Sci. 2002, 21 (2): 209-220. 10.1287/mksc.21.2.209.151.
Article
Google Scholar
Norton JA, Bass FM: A Diffusion Theory Model of Adoption and Substitution for Successive Generations of High-Technology Products. Manag Sci. 1987, 33 (9): 1069-1086. 10.1287/mnsc.33.9.1069.
Article
Google Scholar
van den Bulte C, Stremersch S: Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test. Mark Sci. 2004, 23 (4): 530-544. 10.1287/mksc.1040.0054.
Article
Google Scholar
Talukdar D, Sudhir K, Ainslie A: Investigating New Product Diffusion across Products and Countries. Mark Sci. 2002, 21 (1): 97-114. 10.1287/mksc.21.1.97.161.
Article
Google Scholar
Cohen D: Rosiglitazone: what went wrong?. BMJ. 2010, 341: c4848-10.1136/bmj.c4848.
Article
PubMed
Google Scholar
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004, 364 (9450): 2021-2029. 10.1016/S0140-6736(04)17514-4.
Article
PubMed
Google Scholar
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356 (24): 2457-2471. 10.1056/NEJMoa072761.
Article
CAS
PubMed
Google Scholar
Topol EJ: Failing the Public Health - Rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351 (17): 1707-1709. 10.1056/NEJMp048286.
Article
CAS
PubMed
Google Scholar
Cohen FJ: Entry order as a consideration for innovation strategies. Nat Rev Drug Discov. 2006, 5 (4): 285-294. 10.1038/nrd2009.
Article
CAS
PubMed
Google Scholar
DiMasi JA, Paquette C: The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development. PharmacoEconomics. 2004, 22: 1-14.
Article
PubMed
Google Scholar
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006, 367 (9524): 1747-1757. 10.1016/S0140-6736(06)68770-9.
Article
PubMed
Google Scholar
Expert Panel on Detection E: Treatment of High Blood Cholesterol in A: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.
Article
Google Scholar
Wright M, Upritchard C, Lewis T: A Validation of the Bass New Product Diffusion Model in New Zealand. Mark Bull. 1997, 8: 15-29.
Google Scholar
Fruchter GE, Van den Bulte C: Why the Generalized Bass Model leads to odd optimal advertising policies. Int J Res Mark. , 28 (3): 218-230.
Jiang Z, Bass FM, Bass PI: Virtual Bass Model and the left-hand data-truncation bias in diffusion of innovation studies. Int J Res Mark. 2006, 23 (1): 93-106. 10.1016/j.ijresmar.2006.01.008.
Article
Google Scholar
van den Bulte C, Lilien GL: Bias and Systematic Change in the Parameter Estimates of Macro-Level Diffusion Models. Mark Sci. 1997, 16 (4): 338-353. 10.1287/mksc.16.4.338.
Article
Google Scholar
Iyengar R, Van den Bulte C, Valente TW: Opinion Leadership and Social Contagion in New Product Diffusion. Mark Sci. 2011, 30 (2): 195-212. 10.1287/mksc.1100.0566.
Article
Google Scholar
Coiera E: Why system inertia makes health reform so difficult. BMJ. 2011, 342: d3693-10.1136/bmj.d3693.
Article
PubMed
Google Scholar